FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...
The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...
For years, prostate cancer specialists hit a wall when prostate-specific antigen (PSA) levels crept up after definitive treatment. The cancer was likely back — but where? And to what extent? Bone plus ...
New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...
It does if a single state in the U.S. is any indication. In North Carolina, significantly higher rates of prostate cancer recurrence were reported among men living in rural areas compared to their ...
Racial/ethnic disparities in neoplasm mortality and the role of healthcare access in the United States: Insights from the Global Burden of Disease study study 2000–2019. This is an ASCO Meeting ...
Germany has become a global leader in the treatment of metastatic prostate cancer, offering advanced, individualized care backed by cutting-edge research, innovative technologies, and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results